Kura Oncology, Inc. announced dosing of the first patient with KO-2806, the Company's next-generation farnesyl transferase inhibitor (FTI), in combination with the tyrosine kinase inhibitor (TKI) cabozantinib in the clear cell renal cell carcinoma (ccRCC) cohort of the Phase 1 portion of the FIT-001 trial. Kura Oncology is a next-generation inhibitor of farnesyl transferase inhibitor of farnesyl transferases designed to improve upon the potency, pharmacokinetic and physicochemical properties of earlier FTI drug candidates. At the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Kura presented promising preclinical data supporting the rationale for combining KO-2806 with distinct classes of targeted therapies, including tyrosine kinase inhibitors, KRASG12C inhibitors and KRASG12D inhibitors.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
20.57 USD | -0.96% | -0.63% | +42.56% |
02/05 | Transcript : Kura Oncology, Inc., Q1 2024 Earnings Call, May 02, 2024 | |
02/05 | Kura Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+42.56% | 1.58B | |
+3.62% | 108B | |
+11.04% | 104B | |
+1.28% | 22.33B | |
-12.72% | 22.19B | |
-7.05% | 18.69B | |
-38.36% | 17.74B | |
-10.43% | 17.64B | |
+3.71% | 14.05B | |
+37.44% | 12.51B |
- Stock Market
- Equities
- KURA Stock
- News Kura Oncology, Inc.
- Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma